Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients

Inclusion Criteria:

* Chinese population surgery patients with invasive breast cancer；
* Stage II-III；
* ER positive；
* HER2 negative；
* Ki67≥14%；
* Aged between 18 and 70 years old；
* The maximum diameter of the primary tumor greater than 1cm；
* ECOG score 0-1 points； -Have adequate baseline bone marrow and organ function reserve : absolute neutrophil count ≥ 1500/mm3, platelet count ≥ 8g/dl; the ≥ 100000/mm3 hemoglobin concentration and serum creatinine ≤ 1.5 times the upper limit of normal ; aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal , bilirubin ≤ 1.5 times the upper limit of normal ; left ventricular ejection fraction ( LVEF ) ≥ 50%

Exclusion Criteria: - Non - Chinese population of patients；

* Non- invasive cancer patients;
* Inflammatory Breast Cancer patients;
* Metastatic breast cancer patients;
* HER2 positive patients;
* Ki67\<14% patients;
* No adequateBaseline bone marrow or organ function reserve;
* ECOG PS score ≥ 2 points;
* Younger than 18 years of age or greater than 70 years old;
* Already accepted therapy including chemotherapy , endocrine therapy or targeted therapy before neoadjuvant treatment;
* HER2-positive patients with left ventricular ejection fraction less than 55 % can not receiving Herceptin;
* Known allergy of docetaxel , capecitabine , epirubicin , ring phosphonamide .